• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极早发型炎症性肠病发病机制与治疗的新见解和进展

New Insights and Advances in Pathogenesis and Treatment of Very Early Onset Inflammatory Bowel Disease.

作者信息

Li Qi-Qi, Zhang Hui-Hong, Dai Shi-Xue

机构信息

The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.

Department of Gastroenterology, Guangdong Provincial Geriatrics Institute, National Key Clinical Specialty, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.

出版信息

Front Pediatr. 2022 Mar 1;10:714054. doi: 10.3389/fped.2022.714054. eCollection 2022.

DOI:10.3389/fped.2022.714054
PMID:35299671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8921506/
Abstract

Very early onset inflammatory bowel disease (VEO-IBD) is characterized by multifactorial chronic recurrent intestinal inflammation. Compared with elderly patients, those with VEO-IBD have a more serious condition, not responsive to conventional treatments, with a poor prognosis. Recent studies found that genetic and immunologic abnormalities are closely related to VEO-IBD. Intestinal immune homeostasis monogenic defects (IIHMDs) are changed through various mechanisms. Recent studies have also revealed that abnormalities in genes and immune molecular mechanisms are closely related to VEO-IBD. IIHMDs change through various mechanisms. Epigenetic factors can mediate the interaction between the environment and genome, and genetic factors and immune molecules may be involved in the pathogenesis of the environment and gut microbiota. These discoveries will provide new directions and ideas for the treatment of VEO-IBD.

摘要

极早发型炎症性肠病(VEO-IBD)的特征是多因素导致的慢性复发性肠道炎症。与老年患者相比,VEO-IBD患者病情更严重,对传统治疗无反应,预后较差。最近的研究发现,基因和免疫异常与VEO-IBD密切相关。肠道免疫稳态单基因缺陷(IIHMDs)通过多种机制发生改变。最近的研究还表明,基因和免疫分子机制异常与VEO-IBD密切相关。IIHMDs通过多种机制发生改变。表观遗传因素可介导环境与基因组之间的相互作用,遗传因素和免疫分子可能参与环境和肠道微生物群的发病机制。这些发现将为VEO-IBD的治疗提供新的方向和思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50c9/8921506/4586b96d323f/fped-10-714054-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50c9/8921506/758994de370d/fped-10-714054-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50c9/8921506/4586b96d323f/fped-10-714054-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50c9/8921506/758994de370d/fped-10-714054-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50c9/8921506/4586b96d323f/fped-10-714054-g0002.jpg

相似文献

1
New Insights and Advances in Pathogenesis and Treatment of Very Early Onset Inflammatory Bowel Disease.极早发型炎症性肠病发病机制与治疗的新见解和进展
Front Pediatr. 2022 Mar 1;10:714054. doi: 10.3389/fped.2022.714054. eCollection 2022.
2
The Growing Need to Understand Very Early Onset Inflammatory Bowel Disease.早期发病炎症性肠病的认识需求不断增加。
Front Immunol. 2021 May 26;12:675186. doi: 10.3389/fimmu.2021.675186. eCollection 2021.
3
Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms.以早发性炎症性肠病为模型疾病,鉴定免疫稳态机制的关键调节因子。
Immunol Rev. 2019 Jan;287(1):162-185. doi: 10.1111/imr.12726.
4
Very early onset IBD: novel genetic aetiologies.极早发型炎症性肠病:新的遗传病因
Curr Opin Allergy Clin Immunol. 2018 Dec;18(6):470-480. doi: 10.1097/ACI.0000000000000486.
5
Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies.早期炎症性肠病:以遗传学和潜在免疫缺陷为重点的临床方法。
Inflamm Bowel Dis. 2020 May 12;26(6):820-842. doi: 10.1093/ibd/izz259.
6
Dysregulated inflammasome activity in intestinal inflammation - Insights from patients with very early onset IBD.肠道炎症中失调的炎症小体活性——来自极早发性炎症性肠病患者的见解。
Front Immunol. 2022 Nov 29;13:1027289. doi: 10.3389/fimmu.2022.1027289. eCollection 2022.
7
The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease.儿童非常早发型炎症性肠病的独特疾病进程。
Inflamm Bowel Dis. 2020 May 12;26(6):909-918. doi: 10.1093/ibd/izz214.
8
Current concepts in pediatric inflammatory bowel disease; IL10/IL10R colitis as a model disease.儿童炎症性肠病的当前概念;以IL10/IL10R结肠炎作为模型疾病
Int J Pediatr Adolesc Med. 2019 Mar;6(1):1-5. doi: 10.1016/j.ijpam.2019.02.002. Epub 2019 Mar 12.
9
Genomic and Immunologic Drivers of Very Early-Onset Inflammatory Bowel Disease.极早发型炎症性肠病的基因组和免疫驱动因素
Pediatr Dev Pathol. 2019 May-Jun;22(3):183-193. doi: 10.1177/1093526619834807. Epub 2019 Mar 6.
10
Maintaining intestinal health: the genetics and immunology of very early onset inflammatory bowel disease.维持肠道健康:极早发性炎症性肠病的遗传学与免疫学
Cell Mol Gastroenterol Hepatol. 2015 Sep 1;1(5):462-476. doi: 10.1016/j.jcmgh.2015.06.010.

引用本文的文献

1
Wall of Resilience: How the Intestinal Epithelium Prevents Inflammatory Onslaught in the Gut.韧性之壁:肠道上皮如何预防肠道炎症侵袭
Cell Mol Gastroenterol Hepatol. 2025;19(2):101423. doi: 10.1016/j.jcmgh.2024.101423. Epub 2024 Oct 24.
2
Early diagnosis and treatment of perianal Crohn's disease in a 1-year-old infant: Case report and review of literature.1岁婴儿肛周克罗恩病的早期诊断与治疗:病例报告及文献综述
Clin Case Rep. 2024 May 26;12(6):e8963. doi: 10.1002/ccr3.8963. eCollection 2024 Jun.
3
Changing epidemiology of inflammatory bowel disease in children and adolescents.

本文引用的文献

1
Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease.使用乌司奴单抗治疗药物难治性儿童克罗恩病的经验。
J Pediatr Gastroenterol Nutr. 2021 Nov 1;73(5):610-614. doi: 10.1097/MPG.0000000000003230.
2
Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.芦可替尼:针对自身炎症性疾病的早期发病炎症性肠病的靶向治疗方法。
Clin Gastroenterol Hepatol. 2022 Jun;20(6):1408-1410.e2. doi: 10.1016/j.cgh.2021.07.040. Epub 2021 Jul 27.
3
Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases.
儿童和青少年炎症性肠病的流行情况正在发生变化。
Int J Colorectal Dis. 2024 May 18;39(1):73. doi: 10.1007/s00384-024-04640-9.
4
Circular RNAs in inflammatory bowel disease.环状 RNA 与炎症性肠病。
Front Immunol. 2023 Dec 22;14:1307985. doi: 10.3389/fimmu.2023.1307985. eCollection 2023.
5
Development of Very-Early-Onset Inflammatory Bowel Disease After Multiple Early-Life Antibiotic Exposures: A Case Report and Literature Review.多次早期抗生素暴露后极早发型炎症性肠病的发生:一例报告及文献综述
Cureus. 2023 Jan 16;15(1):e33813. doi: 10.7759/cureus.33813. eCollection 2023 Jan.
6
miR-642a-5p increases glucocorticoid sensitivity by suppressing the TLR4 signalling pathway in THP-1 cells.微小RNA-642a-5p通过抑制THP-1细胞中的Toll样受体4信号通路来提高糖皮质激素敏感性。
Biochem Biophys Rep. 2022 Sep 27;32:101356. doi: 10.1016/j.bbrep.2022.101356. eCollection 2022 Dec.
维多珠单抗治疗极早期炎症性肠病儿科患者的安全性和有效性
J Clin Med. 2021 Jul 5;10(13):2997. doi: 10.3390/jcm10132997.
4
Dual Targeted Therapy for the Management of Inflammatory Bowel Disease.双重靶向治疗用于炎症性肠病的管理。
J Clin Gastroenterol. 2021 Sep 1;55(8):661-666. doi: 10.1097/MCG.0000000000001583.
5
One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.英夫利昔单抗难治性儿童溃疡性结肠炎应用乌司奴单抗治疗的 1 年疗效:一项多中心前瞻性研究。
Aliment Pharmacol Ther. 2021 Jun;53(12):1300-1308. doi: 10.1111/apt.16388. Epub 2021 Apr 28.
6
CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn's disease.环状 RNA_103765 通过海绵吸附 miR-30 家族在克罗恩病中发挥促炎作用。
Sci Rep. 2021 Jan 12;11(1):565. doi: 10.1038/s41598-020-80663-w.
7
Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease.肠内营养独有的作用可介导肠道微生物和代谢变化,这些变化与克罗恩病患儿的缓解相关。
Sci Rep. 2020 Nov 3;10(1):18879. doi: 10.1038/s41598-020-75306-z.
8
Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.双重生物制剂和小分子药物治疗难治性小儿炎症性肠病。
Inflamm Bowel Dis. 2021 Jul 27;27(8):1210-1214. doi: 10.1093/ibd/izaa277.
9
Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease.血清 microRNAs 是与小儿炎症性肠病治疗反应相关的药效生物标志物。
Inflamm Bowel Dis. 2020 Sep 18;26(10):1597-1606. doi: 10.1093/ibd/izaa209.
10
Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.生物制剂联合治疗中重度小儿炎症性肠病:病例系列及文献复习。
Paediatr Drugs. 2020 Aug;22(4):409-416. doi: 10.1007/s40272-020-00396-1.